MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q2
hinzugefügt 10.08.2022
Genmab A/S EBITDA per Share 2011-2026 | GMAB
EBITDA per Share Jährlich Genmab A/S
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 10.4 | 4.41 | 2.4 | 2.32 | 1.83 | 1.3 | 0.493 | 0.159 | -0.221 | - |
Alle Zahlen in DKK-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 10.4 | -0.221 | 2.57 |
EBITDA per Share anderer Aktien in der Pharmaeinzelhändler
| Name | EBITDA per Share | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
0.08 | - | - | $ 866 M |  China |
 |
Exelixis
EXEL
|
3.32 | $ 48.43 | 9.03 % | $ 13.2 B | USA |
 |
Fortress Biotech
FBIO
|
-2.5 | $ 2.56 | 3.96 % | $ 71.4 M | USA |
 |
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Galapagos NV
GLPG
|
-2.53 | $ 28.78 | 1.36 % | $ 2.69 B |  Belgium |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B | France |
 |
Genprex
GNPX
|
-264 | $ 0.9 | 2.02 % | $ 839 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Grifols, S.A.
GRFS
|
0.87 | $ 8.41 | 1.69 % | $ 6.83 B |  Spain |
 |
Athira Pharma
ATHA
|
-23.7 | - | - | $ 269 M | USA |
 |
InflaRx N.V.
IFRX
|
-1.49 | $ 2.47 | 25.39 % | $ 152 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
-1.28 | $ 76.96 | 2.27 % | $ 12.3 B | USA |
 |
Kamada Ltd.
KMDA
|
-0.02 | $ 8.3 | 1.1 % | $ 260 M |  Israel |
 |
BioNTech SE
BNTX
|
62.6 | $ 95.07 | -0.45 % | $ 27.2 B | Germany |
 |
Kymera Therapeutics
KYMR
|
-4.04 | $ 86.14 | 4.15 % | $ 7.28 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-2.84 | - | - | $ 231 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
0.69 | $ 229.83 | -1.06 % | $ 4.2 B | USA |
 |
INmune Bio
INMB
|
-1.91 | $ 1.52 | -1.3 % | $ 37.6 M | USA |
 |
Liquidia Corporation
LQDA
|
-0.58 | $ 41.84 | 4.26 % | $ 3.6 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
0.04 | $ 107.42 | 1.52 % | $ 5.39 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
1.4 | $ 22.32 | -0.13 % | $ 3.7 B | USA |
 |
MannKind Corporation
MNKD
|
0.17 | $ 3.68 | 28.5 % | $ 1.12 B | USA |
 |
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Nanobiotix S.A.
NBTX
|
-1.49 | $ 42.28 | 21.6 % | $ 286 B | France |
 |
Esperion Therapeutics
ESPR
|
0.29 | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-6.03 | $ 3.47 | -8.44 % | $ 5.71 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-2.22 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
0.01 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-0.92 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-6.41 | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-2.19 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-3.02 | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.09 | $ 23.86 | 1.88 % | $ 3.04 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.696 | - | 3.16 % | $ 1.9 M | USA |
 |
Puma Biotechnology
PBYI
|
0.96 | $ 7.5 | 2.04 % | $ 375 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
0.15 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-3.2 | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.72 | - | - | $ 2.17 B | USA |